



Contents lists available at SciVerse ScienceDirect

Research in Veterinary Science

journal homepage: www.elsevier.com/locate/rvsc

Alterations of keratins, involucrin and filaggrin gene expression in canine atopic dermatitis

Sirin Theerawatanasirikul^a, Achariya Sailasuta^a, Roongroje Thanawongnuwech^a,
Gunnaporn Suriyaphol^{b,*}

^a Pathology Unit, Department of Veterinary Pathology, Faculty of Veterinary Science, Chulalongkorn University, Thailand

^b Biochemistry Unit, Department of Veterinary Physiology, Faculty of Veterinary Science, Chulalongkorn University, Thailand

ARTICLE INFO

Article history:

Received 19 March 2012

Accepted 9 June 2012

Available online xxxx

Keywords:

Canine atopic dermatitis

Filaggrin

Involucrin

Keratin

Gene expression

Dog

ABSTRACT

Canine atopic dermatitis (CAD) is a common allergic skin disease in dogs, associated with a defective epidermal barrier. In this study we investigated the alterations in skin keratinocyte proliferation and differentiation in CAD by quantitative reverse transcription-polymerase chain reaction. Gene expression of keratin (*KRT*) markers of proliferative and differentiated keratinocytes, together with that of cornified envelope proteins, involucrin (*IVL*) and filaggrin (*FLG*), were evaluated. An upregulation of *KRT5* and *KRT17* in both lesional and non-lesional AD skin was observed ($p < 0.05$) whereas *KRT2e*, *KRT14*, *IVL* and *FLG* expression were significantly increased only in lesional AD skin ($p < 0.05$). Additionally, the expression levels of *KRT5*, *KRT14*, *KRT17* and *IVL* in CAD were strongly correlated. In conclusion, the expression of the majority of the studied keratins, as well as *IVL* and *FLG* is increased in CAD with close correlation between the proliferative keratins. This is the first report of a correlation of *KRT* and *IVL* genes with CAD.

© 2012 Elsevier Ltd. All rights reserved.

1. Introduction

Atopic dermatitis (AD) is a common allergic skin disease recognized in dogs and humans (Rothe and Grant-Kels, 1996; Hillier and Griffin, 2001). Canine atopic dermatitis (CAD) is a 'genetically predisposed inflammatory and pruritic allergic skin disease with characteristic clinical features associated with IgE antibodies most commonly directed against environmental allergens' (Halliwell, 2006). Approximately 10% of the canine population is affected by CAD (Scott et al., 2001). Disturbances in epidermal differentiation and proliferation lead to a defect in skin barrier permeability that enhances the penetration of environmental allergens (Hudson, 2006; Proksch et al., 2009). In CAD, the structural changes of lesional AD skin have been demonstrated to be epidermal hyperplasia, hyperkeratosis, hypergranulosis and spongiosis (Scott, 1981; Olivry et al., 1997). The correlation of the disease with keratin markers has not yet been studied.

Normal epidermal cell proliferation is restricted to the basal layer where several keratin marker proteins such as *KRT5* and *KRT14* are expressed. Basal cells undergo differentiation and

maturation and move then into the suprabasal compartments where differentiated keratin markers such as *KRT1* and *KRT10* are expressed, whereas *KRT2e* represents late epidermal differentiation (Leigh et al., 1993; Bloor et al., 2003). In humans, keratins *KRT6*, *KRT16*, and *KRT17* have been associated with epidermal hyperproliferation in various diseases, such as psoriasis, basaloid skin tumors, and during wound healing (Leigh et al., 1995; Machesney et al., 1998; Depianto et al., 2010). As keratinocytes differentiate further, several cornified envelope (CE) proteins are synthesized in the granular layer. These proteins include filaggrin (*FLG*), loricrin, involucrin (*IVL*), and S100 proteins. CE proteins help form the outer most layer of the epidermis, the cornified layer, in the final epidermal differentiation and hydrate the skin. The proliferation and differentiation of keratinocytes are important for CE associated protein formation (Steinert and Marekov, 1997; Candi et al., 2005; Proksch et al., 2008). Humans with AD have decreased expression of *FLG* and *IVL* in skin (Seguchi et al., 1996; Jensen et al., 2004). Although the protein expression of *FLG* and *IVL* in CAD has been studied, the association to CAD is still unclear (Marsella et al., 2009; Chervet et al., 2010).

A problem when studying CAD at the protein level is that available antibodies in commerce tested for specificity in dogs are limited. The anti-human filaggrin antibody demonstrated cross-reactivity with canine epidermal proteins (Marsella et al., 2009). The sequencing of the canine genome (Lindblad-Toh et al., 2005) has enabled the study of canine diseases at the transcript level,

* Corresponding author. Address: Biochemistry Unit, Department of Veterinary Physiology, Faculty of Veterinary Science, Chulalongkorn University, 39 Henri Dunant Rd., Pathumwan, Bangkok 10330, Thailand. Tel.: +66 2218 9546; fax: +66 2251 8937.

E-mail address: Gunnaporn.V@chula.ac.th (G. Suriyaphol).

which is more specific to the proteins of interest. The genes encoding human epidermal differentiation complex have been shown to be generally regulated at the transcription level (Segre, 2006). However, genes involved in CAD have been less intensively studied. The aim of this study was to quantify and investigate the correlation between the expression of *KRT1*, *KRT2e*, *KRT5*, *KRT10*, *KRT14*, *KRT17*, *FLG* and *IVL* at the transcript level in lesional atopic, non-lesional atopic and healthy canine skin. Determining the expression pattern of these genes will help, at least in part, our understanding of this disease.

2. Materials and methods

2.1. Animals

Thirty-one dogs were recruited from private small animal clinics. Twenty dogs with AD, comprising twelve Poodles, six Shih tzus and two Pugs, with a mean age of seven years (age range 2–11 years), and eleven healthy control dogs, comprising seven Poodles, three Shih tzus and one Pug, with a mean age of seven years (age range 1–10 years) were used for this study. The diagnosis of CAD was based on compatible history, clinical signs, the presence of 5 signs or more under Favrot's 2010 criteria, and the exclusion of other causes of pruritus (Favrot et al., 2010; Olivry, 2010). Bacterial and yeast infections and ectoparasite infestations were controlled prior to inclusion. No anti-inflammatory medication was given for at least three weeks prior to examination. Control skin samples were obtained from healthy dogs with no history or clinical signs of skin disease. All samples were obtained with the consent of owners following the ethical guidelines required under the Chulalongkorn University Animal Care and Use Committee (CU-ACUC), Thailand.

2.2. Skin biopsies and tissue samples

A 6-mm skin biopsy of 5-mm depth was taken from the ventral abdomen of each dog to minimize variations due to body location. Lesional samples were taken from the skin of 10 atopic dogs with erythema, maculae, papulae or lichenification. Non-lesional samples were obtained from clinically unaffected skin of other 10 atopic dogs. Control samples were obtained from clinically normal dogs. Biopsies were obtained after local anaesthesia with 2% lidocaine and sutured routinely. Subcutaneous fat was removed. The tissues were maintained in RNALater solution overnight at 4 °C

and then stored at –20 °C until processed for quantitative reverse transcriptase polymerase chain reaction (qRT-PCR).

2.3. RNA extraction

The skin tissues in RNALater solution were disrupted in liquid nitrogen to maintain a low temperature. Total RNA was extracted from the skin tissues by homogenization with Trizol reagent (Life Technologies, Carlsbad, CA) and a phenol/chloroform/isopropyl alcohol technique was performed. Subsequently, genomic DNA traces were removed from the RNA with Turbo DNase (Ambion, Austin, TX) to purify the total RNA according to the manufacturer's instructions. The DNase-treated RNA quality and concentration were analyzed using a NanoDrop ND-1000 Spectrophotometer V3.7 (Thermo Fisher Scientific, Waltham, MA).

2.4. Quantitative reverse transcription PCR

cDNA synthesis was performed using the SuperScript III First-strand synthesis system for RT-PCR (Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. Briefly, one microgram of RNA was reverse transcribed in a 20 µL reaction containing 50 ng random primers, 40 U RNase inhibitor and 200 U Superscript III enzyme. qRT-PCR was performed and analyzed on the Rotor Gene 3000 Thermal Cycler (Qiagen, Hilden, Germany). Prior to this study, potentially suitable reference genes were assessed and *RPS19* was demonstrated to be the most stably expressed among different conditions and therefore the most suitable reference gene to normalization. Primer sequences and cycling details for quantitative determination of the housekeeping gene *RPS19* has been previously described (Brinkhof et al., 2006; Wood et al., 2008; Schlotter et al., 2009). Other primers were developed using Primer 3 version 0.4.0 (<http://frodo.wi.mit.edu/>). Primer pairs were investigated for specificity and uniqueness in the dog genome (CanFam2.0, May 2005 assembly) by in silico analysis using In-Silico PCR at the University of California, Santa Cruz Genome Bioinformatics Site (<http://genome.ucsc.edu/>). The primer sequences, accession numbers, and amplicons are depicted in Table 1. PCR reactions were performed in a 10 µL volume containing 1x KAPA SYBR Fast qPCR Master Mix Universal (KAPA Biosystems, Cambridge, MA), 200 nM of each primer and the cDNA template. Thermal cycling conditions were as follows: 95 °C for 2 min followed by 40 cycles at 95 °C for 3 s, 60 °C for 20 s and 72 °C for 1 s. Each reaction was performed in duplicate in three independent runs. Data from the FAM/SYBR channel operating at

Table 1
Primers used in the present study. Indicated are sequences, annealing temperatures in real-time PCR reactions and expected product sizes.

Genes	Accession number	Primers (5'–3')	Amplicon (bp)
Keratin 1 (<i>KRT1</i>)	NM_001003392	Fwd 5' TCTGGAAGGAGAGGAAAGCA 3' Rev 5' ATAAGTCCACACCGTAGC 3'	157
Keratin 2e (<i>KRT2e</i>)	NM_001003386	Fwd 5' AGCTCCATGTCCTCAAGCAT 3' Rev 5' GCCACTTCCAGAGCTGAATC 3'	105
Keratin 5 (<i>KRT5</i>)	XM_003433511	Fwd 5' TCAACAGAGCCCTCTGACT 3' Rev 5' CTTGGTGTCCAGACCTTGT 3'	164
Keratin 10 (<i>KRT10</i>)	NM_001013425	Fwd 5' TTGAGACGCACTGTTCAAGG 3' Rev 5' AGCTCGGATCTGTTGCAGTT 3'	168
Keratin 14 (<i>KRT14</i>)	XM_548101	Fwd 5' CTGAAGGAGGAGCTGGCTTA 3' Rev 5' TTCAGTTCCTCGGCTTGTCT 3'	218
Keratin 17 (<i>KRT17</i>)	XM_548100	Fwd 5' CAACAGCGAGCTGGTACAGA 3' Rev 5' TGTCTCAGCCAGGCTACCTT 3'	130
Involucrin (<i>IVL</i>)	M34442	Fwd 5' AAAGAAGAGCAGGTGCTGGA 3' Rev 5' TGCTCACTGGTGTCTTGAG 3'	203
Filaggrin (<i>FLG</i>)	ENSCAFG0000023034	Fwd 5' GATGACCCAGACACTGCTGA 3' Rev 5' TGGTTTGTCTGATGCTTG 3'	158
Ribosomal protein S19	XM_533657	Fwd 5' CCTTCTCAAAA/GTCTGGG 3' Rev 5' GTTCTCATCTGATGGAGCAAG 3'	95

an excitation maximum 495 nm and an emission maximum 520 nm were evaluated to ensure that PCR amplification had taken place. A melting curve analysis was used to determine the purity of the amplified products. Relative expression levels were calculated by the REST-384 (Relative Expression Software Tool) software with a detection threshold at 0.1. A standard curve was generated for each assay using the fluorescent data from 10-fold serial dilutions of total RNA of the same normal dog and expressed as the target gene normalized to RPS19. Linearity of the obtained standard curves was verified by the R^2 coefficient (Pfaffl, 2001; Pfaffl et al., 2002). A standard curve was then used to calculate the relative amounts of target mRNA in test samples. Quantities of all targets in test samples were normalized to the corresponding RPS19 levels in skin biopsies (Howell et al., 2009).

2.5. Statistic analysis

Statistical analysis of real-time PCR results was performed with REST 384 software, using a pair-wise fixed reallocation randomization test to test for significant differences between groups. Results with a p value <0.05 were considered significant. The correlation analyses were carried out using the Pearson correlation coefficients by GraphPad Prism program, version 5.0 (GraphPad Software, La Jolla, CA); they were interpreted as significant at $p < 0.05$. Hierarchical clustering was performed to analyze the pattern of similarity in gene expression in lesional and nonlesional skin in order to identify gene clusters. It was done by average linkage and Pearson correlation coefficient on $\log_2$ -transformed data, using Multiexperiment Viewer (MeV) program, version 4.8 (Saeed et al., 2003, 2006); the statistical significance level was set at $p < 0.005$.

3. Results

3.1. Alteration of gene expression of *KRT2e*, *KRT5*, *KRT14*, *KRT17*, *IVL* and *FLG* in lesional and non-lesional AD skin

In lesional AD skin, there was a significant increase of *KRT2e*, *KRT5*, *KRT14*, *KRT17*, *IVL* and *FLG* expression compared to normal skin, with fold changes ranging from 3.95 for *KRT2e* to 8.75 for *KRT17*. Only *KRT5* and *KRT17* showed also a statistically significant difference in expression between non-lesional and control skin with fold changes 3.884 and 6.402, respectively. The expression of *KRT1*, *IVL* and *FLG* was upregulated in lesional AD skin compared with non-lesional AD skin with fold changes ranging from 2.90 for *IVL* to 3.23 for *FLG* (Table 2).

From the correlation matrix, there was a close correlation for *KRT5* and *KRT17* levels, both in lesional ($R = 0.906$) and non-lesional AD skin ($R = 0.869$), but not in controls. Strong correlation was also observed between *KRT5* and *KRT14* expression in lesional AD skin ($R = 0.886$) and between *KRT14* and *KRT17* in non-lesional AD skin ($R = 0.856$). For *KRT1*, correlation with *KRT10* in non-lesional AD skin ($R = 0.854$) was absent in AD skin lesions where its new

correlation with *KRT5*, *KRT17*, and *IVL* appeared ($R = 0.867$, 0.961 , 0.833 , respectively). In controls, *KRT2e*, *IVL* and *FLG* showed strong positive correlation which disappeared in lesional and non-lesional AD skin (Tables 3–5).

3.2. Hierarchical clustering of gene expression values in lesional and non-lesional AD skin

Hierarchical clustering was used to study the similarities in patterns of gene expression. In lesional AD skin, *KRT1*, *KRT5*, *KRT14*, *KRT17* and *IVL* were clustered together. Although it was clustered separately, *FLG* showed a similar expression pattern and was placed in the same super-cluster. *KRT10* was clearly different and *KRT2* was an outgroup. In non-lesional AD skin, two super-clusters were observed. *KRT2e*, *KRT5*, *KRT17* and *KRT14* were clustered with *IVL* in one and *KRT1*, *KRT10* and *FLG* in the other, with the two keratins forming a distinct sub-cluster (Fig. 1).

4. Discussion

The present study demonstrated the altered expressions of *KRTs*, *IVL* and *FLG* in CAD. In humans, the keratins have been allocated to two groups: type I acidic keratins (*KRT9–23*), type II basic/neutral keratins (*KRT1–8*) (Moll et al., 1982; Fuchs and Weber, 1994), pairing up as heteropolymeric filaments in epithelia (Parry et al., 1985). In the dog, acidic (type I) and basic (type II) keratin genes were found on chromosomes 9 and 27, respectively (Keller et al., 1998; Miller et al., 1999). *KRT1* and *KRT2e* genes were shown to be highly conserved with high homology to their human counterparts (Credille et al., 2005). In our study, a pair of type I and its type II keratin partner genes, *KRT5* and *KRT14*, a marker of mitotically active basal cells of the epidermis, was found to be coordinately expressed in lesional CAD whereas a pair of *KRT1* and *KRT10* was not shown to be significantly upregulated. The expression of *KRT5* and *KRT14* was reported to be turned off prior to the expression of a *KRT1* and *KRT10* pair (Fuchs and Green, 1980). CAD exhibits epidermal hyperplasia, hyperkeratosis, hypergranulosis and spongiosis (Scott, 1981; Olivry et al., 1997). In our study, the upregulation of *KRT5* and *KRT14*, together with that of *KRT17*, a hyperproliferative marker (Leigh et al., 1995; Machesney et al., 1998), and *KRT2e*, which is normally expressed in the granular layer (Collin et al., 1992), indicates that the histopathological characteristics of CAD might, at least in part, be due to the upregulation of these *KRTs*. *KRT5* and *KRT17* expression was increased even in non-lesional AD skin, indicating that both are sensitive markers of CAD. The *KRT5*, *KRT14* and *KRT17* genes were upregulated in CAD compared to control samples. In addition, they exhibited a strong correlation of expression levels in both lesional and non-lesional AD skin (Tables 4 and 5 and Fig. 1), probably indicating that the genes were activated in response to CAD. The functional pathway and how gene products interact should be further studied.

Table 2
Fold change in gene-specific mRNA expression in CAD lesional, CAD non-lesional and control dog skin.

Gene	Lesion vs. normal		Non-lesion vs. normal		Lesion vs. non-lesion	
	Fold change	<i>p</i> Value*	Fold change	<i>p</i> Value*	Fold change	<i>p</i> Value*
<i>KRT1</i>	2.906	0.075	0.941	0.911	3.088	0.047
<i>KRT2e</i>	3.948	0.027	1.609	0.492	2.453	0.202
<i>KRT5</i>	4.947	0.009	3.884	0.011	1.274	0.597
<i>KRT10</i>	1.271	0.467	0.773	0.520	1.643	0.238
<i>KRT14</i>	6.008	0.010	2.273	0.138	2.643	0.186
<i>KRT17</i>	8.751	0.001	6.402	0.002	1.367	0.561
<i>IVL</i>	4.793	0.003	1.651	0.289	2.903	0.014
<i>FLG</i>	4.040	0.001	1.252	0.576	3.226	0.009

* Pair wise fixed reallocation randomization test normalized by reference gene. Results in italics indicate a significant difference ($p < 0.05$).

Table 3

Correlation between individual transcript levels in skin biopsies from clinically normal dogs (controls).

	<i>KRT1</i>	<i>KRT2e</i>	<i>KRT5</i>	<i>KRT10</i>	<i>KRT14</i>	<i>KRT17</i>	<i>IVL</i>	<i>FLG</i>
<i>KRT1</i>	1							
<i>KRT2e</i>	–0.005 0.989	1						
<i>KRT5</i>	–0.020 0.956	0.751 0.012	1					
<i>KRT10</i>	–0.107 0.768	0.0929 0.799	0.199 0.580	1				
<i>KRT14</i>	0.855 0.002	–0.122 0.737	–0.323 0.363	–0.394 0.260	1			
<i>KRT17</i>	0.801 0.005	0.004 0.990	0.144 0.692	0.132 0.716	0.488 0.152	1		
<i>IVL</i>	–0.070 0.846	0.959 <0.0001	0.670 0.034	–0.121 0.739	–0.114 0.755	–0.078 0.832	1	
<i>FLG</i>	–0.109 0.765	0.986 <0.0001	0.721 0.018	0.0073 0.984	–0.182 0.615	–0.103 0.778	0.969 <0.0001	1

Pearson's correlation coefficients for each pair of genes are shown. A significant correlation (a correlation at $p < 0.005$) is marked by italics.**Table 4**

Correlation between individual transcript levels in lesional AD skin biopsies.

	<i>KRT1</i>	<i>KRT2e</i>	<i>KRT5</i>	<i>KRT10</i>	<i>KRT14</i>	<i>KRT17</i>	<i>IVL</i>	<i>FLG</i>
<i>KRT1</i>	1							
<i>KRT2e</i>	0.257 0.474	1						
<i>KRT5</i>	0.867 0.001	0.194 0.591	1					
<i>KRT10</i>	–0.113 0.756	–0.104 0.775	–0.388 0.268	1				
<i>KRT14</i>	0.633 0.049	–0.174 0.631	0.886 0.001	–0.471 0.169	1			
<i>KRT17</i>	0.961 <0.0001	0.250 0.485	0.906 0.0002	–0.301 0.399	0.699 0.024	1		
<i>IVL</i>	0.833 0.003	0.465 0.175	0.522 0.122	0.0258 0.947	0.203 0.573	0.777 0.008	1	
<i>FLG</i>	0.486 0.154	–0.393 0.261	0.505 0.136	0.388 0.268	0.590 0.072	0.433 0.211	0.207 0.566	

Pearson's correlation coefficients for each pair of genes are shown. A significant correlation (a correlation at $p < 0.005$) is marked by italics.**Table 5**

Correlation between individual transcript levels in non-lesional AD skin biopsies.

	<i>KRT1</i>	<i>KRT2e</i>	<i>KRT5</i>	<i>KRT10</i>	<i>KRT14</i>	<i>KRT17</i>	<i>IVL</i>	<i>FLG</i>
<i>KRT1</i>	1							
<i>KRT2e</i>	0.600 0.067	1						
<i>KRT5</i>	–0.288 0.420	0.207 0.567	1					
<i>KRT10</i>	0.854 0.002	0.740 0.014	0.021 0.953	1				
<i>KRT14</i>	–0.160 0.658	0.564 0.089	0.701 0.024	0.052 0.885	1			
<i>KRT17</i>	–0.067 0.857	0.505 0.136	0.869 0.001	0.152 0.675	0.856 0.001	1		
<i>IVL</i>	–0.673 0.033	–0.087 0.810	0.455 0.186	–0.478 0.162	0.618 0.057	0.488 0.152	1	
<i>FLG</i>	–0.100 0.782	0.002 0.995	–0.082 0.820	0.123 0.735	–0.064 0.861	–0.304 0.392	–0.250 0.487	1

Pearson's correlation coefficients for each pair of genes are shown. A significant correlation (a correlation at $p < 0.005$) is marked by italics.

In humans, during epidermal differentiation, IVL and FLG play a crucial role in the formation of the CE, contributing to the skin's barrier function (Steinert and Marekov, 1997; Candi et al., 2005; Proksch et al., 2008). In our study, the up-regulation of *IVL* and *FLG* mRNA expression was observed in lesional AD skin compared to the controls. A significant increase of *IVL* RNA was described in

lesional human atopic dermatitis (HAD) skin (Jarzab et al., 2010) which was consistent with a report of a distinct rise of immature IVL protein in the stratum corneum of lesional AD skin of HAD (Hirao et al., 2003). IVL protein expression has been demonstrated in CAD (Chervet et al., 2010). However, other studies have shown that IVL expression was decreased in HAD skin lesions (Jensen




Fig. 1. Hierarchical clustering of genes in lesional (A) and non-lesional (B) skin. KRT = keratin; IVL = involucrin; FLG = filaggrin; d = dog.

et al., 2004; Sugiura et al., 2005). In our study, *IVL* showed closer correlation with *KRT5*, *KRT14* and *KRT17* than with *FLG*, suggesting that *IVL* and a group of *KRT* probably behaved as coexpression partners. Further investigation of *IVL* expression pathway in CAD is required. Contrary to the downregulation of *FLG* mRNA in experimentally challenged atopic beagles (Santoro et al., 2010b), our study showed a significant upregulation of *FLG* RNA in lesional AD skin (Table 2). The upregulated *FLG* and *IVL* genes were probably the response of skin cells to compensate abnormal function in AD. At the protein level, reduced *FLG* protein expression in laboratory beagles, with induced CAD, was reported (Marsella et al., 2009), but no significant differences of *FLG* expression between normal and induced CAD models was described (Santoro et al., 2010a,b). Thus, further work regarding the association of this gene with CAD should be performed.

5. Conclusion

In conclusion, this study identified novel players in CAD pathology. *KRT5*, *KRT14*, *KRT17*, and *IVL* gene expression was shown for the first time to be associated with the disease. For future work, the correlation of epidermal proliferation and differentiation to *KRTs*, *FLG*, *IVL* protein expression should be confirmed and investigated in CAD.

Conflict of interests

None of the authors has any financial or personal relationships that could inappropriately influence or bias the content of the paper.

Acknowledgements

We would like to express our thanks to Drs. Tossaporn Nakbed and Jakkaphan Wannawong for sample collections. Special thanks to Dr. Charles E. Chapple, TAGC Inserm U928, Université de la Méditerranée, for proofreading of our manuscript. This study was supported by the Ratchadaphiseksomphot Endowment Fund (Grant No. R_008_2553) and in part by a grant funded under the program Strategic Scholarships for Frontier Research Network for the Joint Ph.D. Program Thai Doctoral Degree from the Office of the Higher Education Commission, Thailand (Grant number: 152/2551).

References

- Bloor, B.K., Tidman, N., Leigh, I.M., Odell, E., Dogan, B., Wollina, U., Ghali, L., Waseem, A., 2003. Expression of keratin K2e in cutaneous and oral lesions: association with keratinocyte activation, proliferation, and keratinization. *American Journal of Pathology* 162, 963–975.
- Brinkhof, B., Spee, B., Rothuizen, J., Penning, L.C., 2006. Development and evaluation of canine reference genes for accurate quantification of gene expression. *Analytical Biochemistry* 356, 36–43.
- Candi, E., Schmidt, R., Melino, G., 2005. The cornified envelope: a model of cell death in the skin. *Nature Reviews. Molecular Cell Biology* 6, 328–340.
- Chervet, L., Galichet, A., McLean, W.H., Chen, H., Suter, M.M., Roosje, P.J., Müller, E.J., 2010. Missing C-terminal filaggrin expression, NFκB activation and hyperproliferation identify the dog as a putative model to study epidermal dysfunction in atopic dermatitis. *Experimental Dermatology* 19, e343–e346.
- Collin, C., Moll, R., Kubicka, S., Ouhayoun, J.P., Franke, W.W., 1992. Characterization of human cytokeratin 2, an epidermal cytoskeletal protein synthesized late during differentiation. *Experimental Cell Research* 202, 132–141.
- Credille, K.M., Guyon, R., André, C., Murphy, K., Tucker, K., Barnhart, K.F., Dunstan, R.W., 2005. Comparative sequence analysis and radiation hybrid mapping of two epidermal type II keratin genes in the dog: keratin 1 and keratin 2e. *Cytogenetic and Genome Research* 108, 328–332.
- Depianto, D., Kerns, M.L., Dlugosz, A.A., Coulombe, P.A., 2010. Keratin 17 promotes epithelial proliferation and tumor growth by polarizing the immune response in skin. *Nature Genetics* 42, 910–914.
- Favrot, C., Steffan, J., Seewald, W., Picco, F., 2010. A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis. *Veterinary Dermatology* 21, 23–31.
- Fuchs, E., Green, H., 1980. Changes in keratin gene expression during terminal differentiation of the keratinocyte. *Cell* 19, 1033–1042.
- Fuchs, E., Weber, K., 1994. Intermediate filaments: structure, dynamics, function, and disease. *Annual Review of Biochemistry* 63, 345–382.
- Halliwel, R., 2006. Revised nomenclature for veterinary allergy. *Veterinary Immunology and Immunopathology* 114, 2007–2008.
- Hillier, A., Griffin, C.E., 2001. The ACVD task force on canine atopic dermatitis (I): incidence and prevalence. *Veterinary Immunology and Immunopathology* 81, 147–151.
- Hirao, T., Terui, T., Takeuchi, I., Kobayashi, H., Okada, M., Takahashi, M., Tagami, H., 2003. Ratio of immature cornified envelopes does not correlate with parakeratosis in inflammatory skin disorders. *Experimental Dermatology* 12, 591–601.
- Howell, M.D., Kim, B.E., Gao, P., Grant, A.V., Boguniewicz, M., DeBenedetto, A., Schneider, L., Beck, L.A., Barnes, K.C., Leung, D.Y., 2009. Cytokine modulation of atopic dermatitis filaggrin skin expression. *Journal of Allergy and Clinical Immunology* 124, R7–R12.
- Hudson, T.J., 2006. Skin barrier function and allergic risk. *Nature Genetics* 38, 399–400.
- Jarzab, J., Filipowska, B., Zebracka, J., Kowalska, M., Bozek, A., Rachowska, R., Gubala, E., Grzanka, A., Hadas, E., Jarzab, B., 2010. Locus 1q21 gene expression changes in atopic dermatitis skin lesions: deregulation of small proline-rich region 1A. *International Archives of Allergy and Immunology* 151, 28–37.
- Jensen, J.M., Folster-Holst, R., Baranowsky, A., Schunck, M., Winoto-Morbach, S., Neumann, C., Schütze, S., Proksch, E., 2004. Impaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis. *Journal of Investigative Dermatology* 122, 1423–1431.
- Keller, R.C., Switonski, M., Jorg, H., Ladon, D., Arnold, S., Schelling, C., 1998. Chromosomal assignment of two putative canine keratin gene clusters. *Animal Genetics* 29, 141–143.
- Leigh, I.M., Purkis, P.E., Whitehead, P., Lane, E.B., 1993. Monospecific monoclonal antibodies to keratin 1 carboxy terminal (synthetic peptide) and to keratin 10 as markers of epidermal differentiation. *British Journal of Dermatology* 129, 110–119.
- Leigh, I.M., Navsaria, H., Purkis, P.E., McKay, I.A., Bowden, P.E., Riddle, P.N., 1995. Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. *British Journal of Dermatology* 133, 501–511.
- Lindblad-Toh, K., Wade, C.M., Mikkelsen, T.S., Karlsson, E.K., Jaffe, D.B., Kamal, M., Clamp, M., Chang, J.L., Kulbokas 3rd, E.J., Zody, M.C., Mauceli, E., Xie, X., Breen, M., Wayne, R.K., Ostrander, E.A., Ponting, C.P., Galibert, F., Smith, D.R., DeJong, P.J., Kirkness, E., Alvarez, P., Biagi, T., Brockman, W., Butler, J., Chin, C.W., Cook, A., Cuff, J., Daly, M.J., DeCaprio, D., Gnerre, S., Grabherr, M., Kellis, M., Kleber, M., Bardeleben, C., Goodstadt, L., Heger, A., Hitte, C., Kim, L., Koepfli, K.P., Parker, H.G., Pollinger, J.P., Searle, S.M., Sutter, N.B., Thomas, R., Webber, C., Baldwin, J., Abebe, A., Abouelleil, A., Aftuck, L., Ait-Zahra, M., Aldredge, T., Allen, N., An, P., Anderson, S., Antoine, C., Arachchi, H., Aslam, A., Ayotte, L., Bachantsang, P., Barry, A., Bayul, T., Benamara, M., Berlin, A., Bessette, D., Blitshteyn, B., Bloom, T., Blye, J., Boguslavskiy, L., Bonnet, C., Boukhgalter, B., Brown, A., Cahill, P., Calixte, N., Camarata, J., Cheshatsang, Y., Chu, J., Citroen, M., Collymore, A., Cooke, P., Dawoe, T., Daza, R., Decktor, K., DeGray, S., Dhargay, N., Dooley, K., Dorje, P., Dorjee, K., Dorris, L., Duffey, N., Dupes, A., Egbremolen, O., Elong, R., Falk, J., Farina, A., Faro, S., Ferguson, D., Ferreira, P., Fisher, S., FitzGerald, M., Foley, K., Foley, C., Franke, A., Friedrich, D., Gage, D., Garber, M., Gearin, G., Giannoukos, G., Goode, T., Goyette, A., Graham, J., Grandbois, E., Gyaltsen, K., Hafez, N., Hagopian, D., Hagos, B., Hall, J., Healy, C., Hegarty, R., Honan, T., Horn, A., Houde, N., Hughes, L., Hunnicutt, L., Husby, M., Jester, B., Jones, C., Kamat, A., Kanga, B., Kells, C., Khazanovich, D., Kieu, A.C., Kisner, P., Kumar, M., Lance, K., Landers, T.,

- Lara, Lee, W., Leger, J.P., Lennon, N., Leuper, L., LeVine, S., Liu, J., Liu, X., Lokyitsang, Y., Lokyitsang, T., Lui, A., Macdonald, J., Major, J., Marabella, R., Maru, K., Matthews, C., McDonough, S., Mehta, T., Meldrim, J., Melnikov, A., Meneus, L., Mihalev, A., Mihova, T., Miller, K., Mittelman, R., Mlenga, V., Mulrain, L., Munson, G., Navidi, A., Naylor, J., Nguyen, T., Nguyen, N., Nguyen, C., Nicol, R., Norbu, N., Norbu, C., Novod, N., Nyima, T., Olandt, P., O'Neill, B., O'Neill, K., Osman, S., Oyono, L., Patti, C., Perrin, D., Phunkhang, P., Pierre, F., Priest, M., Rachupka, A., Raghuraman, S., Rameau, R., Ray, V., Raymond, C., Rege, F., Rise, C., Rogers, J., Rogov, P., Sahalie, J., Settupalli, S., Sharpe, T., Shea, T., Sheehan, M., Sherpa, N., Shi, J., Shih, D., Sloan, J., Smith, C., Sparrow, T., Stalker, J., Stange-Thomann, N., Stavropoulos, S., Stone, C., Stone, S., Sykes, S., Tchuinga, P., Tenzing, P., Tesfaye, S., Thoulutsang, D., Thoulutsang, Y., Topham, K., Topping, I., Tsamla, T., Vassiliev, H., Venkataraman, V., Vo, A., Wangchuk, T., Wangdi, T., Weiland, M., Wilkinson, J., Wilson, A., Yadav, S., Yang, S., Yang, X., Young, G., Yu, Q., Zainoun, J., Zembek, L., Zimmer, A., Lander, E.S., . Genome sequence, comparative analysis and haplotype structure of the domestic dog. *Nature* 438, 803–819.
- Machesney, M., Tidman, N., Waseem, A., Kirby, L., Leigh, I., 1998. Activated keratinocytes in the epidermis of hypertrophic scars. *American Journal of Pathology* 152, 1133–1141.
- Marsella, R., Samuelson, D., Harrington, L., 2009. Immunohistochemical evaluation of filaggrin polyclonal antibody in atopic and normal beagles. *Veterinary Dermatology* 20, 547–554.
- Miller, A.B., Breen, M., Murphy, K.E., 1999. Chromosomal localization of acidic and basic keratin genes of the domestic dog. *Mammalian Genome* 10, 371–375.
- Moll, R., Franke, W.W., Schiller, D.L., Geiger, B., Krepler, R., 1982. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. *Cell* 31, 11–24.
- Olivry, T., Naydan, D.K., Moore, P.F., 1997. Characterization of the cutaneous inflammatory infiltrate in canine atopic dermatitis. *American Journal of Dermatopathology* 19, 477–486.
- Olivry, T., 2010. New diagnostic criteria for canine atopic dermatitis. *Veterinary Dermatology* 21, 123–126.
- Parry, D.A., Steven, A.C., Steinert, P.M., 1985. The coiled-coil molecules of intermediate filaments consist of two parallel chains in exact axial register. *Biochemical and Biophysical Research Communications* 127, 1012–1018.
- Pfaffl, M.W., 2001. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Research* 29, e45.
- Pfaffl, M.W., Horgan, G.W., Dempfle, L., 2002. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. *Nucleic Acids Research* 30, e36.
- Proksch, E., Brandner, J.M., Jensen, J.M., 2008. The skin: an indispensable barrier. *Experimental Dermatology* 17, 1063–1072.
- Proksch, E., Fölster-Holst, R., Bräutigam, M., Sepehrmanesh, M., Pfeiffer, S., Jensen, J.M., 2009. Role of the epidermal barrier in atopic dermatitis. *Journal of the German Society of Dermatology* 7, 899–910.
- Rothe, M.J., Grant-Kels, J.M., 1996. Atopic dermatitis: an update. *Journal of the American Academy of Dermatology* 35, 1–13.
- Saeed, A.I., Bhagabati, N.K., Braisted, J.C., Liang, W., Sharov, V., Howe, E.A., Li, J., Thiagarajan, M., White, J.A., Quackenbush, J., 2006. TM4 microarray software suite. *Methods in Enzymology* 411, 134–193.
- Saeed, A.I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M., Currier, T., Thiagarajan, M., Sturn, A., Snuffin, M., Rezantsev, A., Popov, D., Ryltsov, A., Kostukovich, E., Borisovsky, I., Liu, Z., Vinsavich, A., Trush, V., Quackenbush, J., 2003. TM4: a free, open-source system for microarray data management and analysis. *Bio Techniques* 34, 374–378.
- Santoro, D., Marsella, R., Bunick, D., Ahrens, K., Graves, T.K., Campbell, K.L., 2010a. Long-term effect of probiotics on filaggrin mRNA and protein expression in atopic beagles. NAVDF 2010 Abstracts. *Veterinary Dermatology* 21, 322.
- Santoro, D., Marsella, R., Bunick, D., Graves, T.K., Campbell, K.L., Ahrens, K., 2010b. Expression and distribution of canine filaggrin in the skin of healthy and atopic beagles. NAVDF 2010 Abstracts. *Veterinary Dermatology* 21, 323.
- Schlotter, Y.M., Veenhof, E.Z., Brinkhof, B., Rutten, V.P., Spee, B., Willemse, T., Penning, L.C., 2009. A GeNorm algorithm-based selection of reference genes for quantitative real-time PCR in skin biopsies of healthy dogs and dogs with atopic dermatitis. *Veterinary Immunology and Immunopathology* 129, 115–118.
- Scott, D.W., 1981. Observations on canine atopy. *Journal of American Animal Hospital Association* 17, 91–100.
- Scott, D.W., Miller, W.H., Griffin, C.E. (Eds.), 2001. *Small Animal Dermatology*, sixth ed. W.B. Saunders, Philadelphia, PA, pp. 574–601.
- Segre, J.A., 2006. Epidermal barrier formation and recovery in skin disorders. *Journal of Clinical Investigation* 116, 1150–1158.
- Seguchi, T., Cui, C.Y., Kusuda, S., Takahashi, M., Aisu, K., Tezuka, T., 1996. Decreased expression of filaggrin in atopic skin. *Archives of Dermatological Research* 288, 442–446.
- Steinert, P.M., Marekov, L.N., 1997. Direct evidence that involucrin is a major early isopeptide cross-linked component of the keratinocyte cornified cell envelope. *Journal of Biological Chemistry* 272, 2021–2030.
- Sugiura, H., Ebise, H., Tazawa, T., Tanaka, K., Sugiura, Y., Uehara, M., Kikuchi, K., Kimura, T., 2005. Large-scale DNA microarray analysis of atopic skin lesions shows overexpression of an epidermal differentiation gene cluster in the alternative pathway and lack of protective gene expression in the cornified envelope. *British Journal of Dermatology* 152, 146–149.
- Wood, S.H., Clements, D.N., McEwan, N.A., Nuttall, T., Carter, S.D., 2008. Reference genes for canine skin when using quantitative real-time PCR. *Veterinary Immunology and Immunopathology* 126, 392–395.